QSIT Is Ending. Are You Ready for What Comes Next? 

After 25 years, the FDA is retiring the Quality System Inspection Technique (QSIT). In a recent webinar, the FDA confirmed that a new inspection methodology will replace QSIT on or before the QMSR effective date of February 2, 2026. 

This change signals a major shift in FDA inspections, and organizations must prepare now for a very different approach. ComplianceQuest is here to help your organization understand what can be done, if it is not done already, to prepare. For some companies this change is minor because they already have an integrated QMS. For others stuck in the dark ages of paper driven records, they need help. 

The implementation of the QMSR Inspection Program by the FDA is likely to lead to several changes in the life sciences sector: 

• Enhanced Focus on Quality Management: Companies may prioritize the development and maintenance of robust integrated and connected quality management systems, as these will be closely scrutinized during inspections. This could lead to improved product quality and safety.
• Increased Regulatory Scrutiny: The integration of inspection processes into Compliance Programs may result in more frequent and comprehensive audits by the FDA. Companies will need to be prepared for a deeper examination of their quality practices.
• Adaptation of Compliance Strategies: Life sciences companies will likely need to revise their compliance strategies and training programs to align with the new inspection framework. This could involve investing in new technologies or methodologies to monitor and improve quality.
• Shift in Documentation Practices: With an emphasis on integrated inspection, companies might need to focus on more streamlined and accessible documentation of their quality processes. This could reduce the burden of compliance documentation while ensuring that necessary information is readily available.
• Increased Collaboration and Communication: Enhanced relationships with regulatory bodies may emerge, as companies may need to engage more proactively with the FDA to clarify expectations and compliance strategies.
• Potential for Innovation in Quality Systems: As companies strive to meet new regulatory standards, there may be an increase in innovation around quality management practices, tools, and technologies that facilitate better compliance and operational efficiency. One innovation of the use of an eQMS that enables audit ready records – all of the time!
• Cultural Shift Towards Quality: A stronger emphasis on quality management as a system might foster a cultural transformation within organizations, encouraging all employees to take ownership of quality and compliance responsibilities across various departments.

Overall, these changes will likely lead to a more committed approach to quality and compliance within the life sciences industry, ultimately benefiting public health by ensuring safer and more effective products